SCYX plans Phase II trial of SCY-770 for ADPKD by year-end
SCYX said phase II trials for SCY-770 in ADPKD are set to begin by year-end, as part of its rare-disease pipeline following the acquisition of SCY-770.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.